Loss of muscle mass can result in: Decreased strength and endurance Slower metabolism Impaired balance and mobility Increased risk of falls or fractures Difficulty with everyday tasks like climbing stairs, standing up from a chair, or lifting groceries Similarly, reduced bone density during weight loss can increase the risk of osteoporosis and fractures, especially in postmenopausal women and older adults
however, there is a lack of data supporting CV risk reduction in patients with clinical ASCVD
GPX is a gene that makes an enzyme, also of the same name
Glutathione is vital for the proper function of white blood cells
Injectable Semaglutide has gained widespread recognition for its remarkable success in aiding weight loss
(This is associative evidence and may reflect confounding by indication, surveillance patterns, and glycaemic differences.) For post-marketing pharmacovigilance, FAERS-based analyses of semaglutide identify multiple safety signals (e.g., gastrointestinal obstruction-related terms, dehydration/volume depletion in some GLP-1RA analyses), but vulvovaginal dryness/infection/discharge/pain are not prominent as labelled risks in the major semaglutide FAERS disproportionality paper retrieved here
